Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$3.00M+341.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Laurent Levy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 97
- Beta
- 0.57
- Country
- FR
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 1.68
Financials
Revenue
$3.00M+341.8%Net Income
$-18.58MEBITDA
$-13.16MFree Cash Flow
$-16.41MEPS (diluted)
$-0.39Shares Outstanding (diluted)
47.82M+3014.3%Operating Expenses
$17.51MCash & Debt
$52.75MReturn of Capital
$0.00Revenue by Segment (annual)
$52.34MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.64M | $-23.96M | $-0.50 |
| 2024 | $-7.19M | $-68.13M | $-1.44 |
| 2023 | $36.21M | $-39.70M | $-1.08 |
| 2022 | $4.78M | $-57.04M | $-1.64 |
| 2021 | $2.65M | $-47.00M | $-1.35 |
| 2020 | $2.33M | $-33.59M | $-1.38 |
| 2019 | $2.54M | $-50.91M | $-2.35 |
| 2018 | $3.48M | $-30.34M | $-1.52 |
| 2017 | $3.72M | $-26.14M | $-1.50 |
| 2016 | $5.42M | $-21.88M | $-1.43 |
| 2015 | $4.02M | $-17.00M | $-1.20 |
| 2014 | $2.77M | $-9.56M | $-0.74 |
| 2013 | $1.60M | $-8.14M | $-0.76 |
| 2012 | $970.6K | $-5.33M | $-0.65 |
Valuation
NBTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·4h ago·Neutral
NANOBIOTIX Provides First Half 2026 Operational and Financial Update PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
View source ↗
Earnings
Tue, Sep 29(in 4 days)
Consensus estimate $-0.48 per share
Typical surprise -22.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Mar 31$-0.46 vs $0.30miss
- Tue, Sep 30$-0.13 vs $-0.25beat
- Wed, Apr 2$-1.01 vs $-0.62miss
- Tue, Nov 12$-0.50 vs $-0.51beat
- Wed, Apr 24$-0.33 vs $-0.83beat
- Mon, Nov 13$-0.87 vs $-0.59miss
Estimates and results for NBTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in NBTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.